noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Edward J. Markey

Sens. Markey and Blumenthal Introduce New Safety Legislation for[...]
City of Boston, MA

Notice of Finding of No Significant Impact and Notice of Intent to[...]
State of Indiana

[SUPREME] Tervarus L. Gary v. State of Indiana, No. 25S-CR-00265

Healthcare

Zevra Therapeutics Inc.

12/17/2025 | Press release | Distributed by Public on 12/17/2025 15:16

Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On December 11, 2025, the board of directors (the "Board") of Zevra Therapeutics, Inc. (the "Company") appointed Timothy Sangiovanni, the Company's current Senior Vice President, Finance and Corporate Controller and principal accounting officer, as interim principal financial officer, effective as of January 1, 2026. Mr. Sangiovanni has served as Senior Vice President, Finance and Corporate Controller of the Company since January 2023. Prior to that, he served as Vice President, Corporate Controller from February 2017 to January 2023 and Director of Financial Reporting from August 2015 to February 2017. There was no change to Mr. Sangiovanni's compensation arrangements in connection with his appointment as interim principal financial officer.

Zevra Therapeutics Inc. published this content on December 17, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 17, 2025 at 21:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]